| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| 6 months symptomatic COVID | 0.09 [0.07, 0.11] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | crucial | - |
| confirmed Covid-19, from 1st dose | 0.17 [0.13, 0.22] | | < 1 | | 0% | 2 studies (1/1) | 100.0 % | low | not evaluable | high | crucial | - |
| deaths | 0.09 [0.05, 0.19] | | < 1 | | 94% | 4 studies (1/3) | 100.0 % | NA | not evaluable | | crucial | - |
| vaccine efficacy from randomization (ITT) | 0.18 [0.13, 0.25] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | crucial | - |
| confirmed COVID (any severity) | 0.21 [0.10, 0.42] | | < 1 | | 99% | 7 studies (-/7) | 100.0 % | NA | not evaluable | | important | - |
| hospitalization | 0.11 [0.05, 0.20] | | < 1 | | 99% | 7 studies (-/7) | 100.0 % | low | not evaluable | high | important | - |
| symptomatic Covid-19 | 0.14 [0.07, 0.27] | | < 1 | | 99% | 16 studies (1/15) | 100.0 % | low | low | high | important | - |
| 6 months severe COVID-19 | 0.03 [0.00, 0.46] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
| asymptomatic COVID case | 0.16 [0.08, 0.35] | | < 1 | | 91% | 4 studies (-/4) | 100.0 % | NA | not evaluable | | non important | - |
| infection (PCR positive symptomatic or not) | 0.16 [0.10, 0.26] | | < 1 | | 98% | 11 studies (-/11) | 100.0 % | low | critical | high | non important | - |
| severe COVID-19 occurrence | 0.09 [0.05, 0.17] | | < 1 | | 97% | 9 studies (1/8) | 100.0 % | moderate | not evaluable | moderate | non important | - |
| transmission (symptomatic confirmed COVID19) | 0.53 [0.48, 0.58] | | < 1 | | 0% | 2 studies (-/2) | 100.0 % | serious | not evaluable | low | non important | - |
| vaccine efficacy after dose 1 (and before dose 2) | 0.29 [0.19, 0.46] | | < 1 | | 75% | 6 studies (1/5) | 100.0 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| cerebrovascular thromboembolic events | 0.84 [0.55, 1.29] | | < 1 | | 0% | 1 study (-/1) | 78.8 % | NA | not evaluable | | important | - |
| related AE (TRAE) | 4.91 [4.58, 5.26] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | important | - |
| related SAE (TRSAE) | 8.00 [0.42, 151.43] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | important | - |
| serious adverse events | 1.14 [0.88, 1.47] | | < 1 | | 0% | 1 study (1/-) | 16.4 % | NA | not evaluable | | important | - |
| acute kidney injury | 0.44 [0.25, 0.78] | | < 1 | | 0% | 1 study (-/1) | 99.7 % | NA | not evaluable | | non important | - |
| adverse events | 2.62 [2.49, 2.76] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Anemia | 0.79 [0.67, 0.93] | | < 1 | | 0% | 1 study (-/1) | 99.8 % | NA | not evaluable | | non important | - |
| arrhythmia | 0.89 [0.75, 1.06] | | < 1 | | 0% | 1 study (-/1) | 91.0 % | NA | not evaluable | | non important | - |
| Arthritis or arthropathy | 0.95 [0.66, 1.36] | | < 1 | | 0% | 1 study (-/1) | 60.9 % | NA | not evaluable | | non important | - |
| convulsions/seizures | 1.03 [0.85, 1.26] | | < 1 | | 0% | 2 studies (-/2) | 37.8 % | critical | not evaluable | very low | non important | - |
| deep vein thrombosis | 0.87 [0.55, 1.39] | | < 1 | | 0% | 1 study (-/1) | 72.0 % | NA | not evaluable | | non important | - |
| disseminated intravascular coagulation | 0.70 [0.39, 1.27] | | < 1 | | 0% | 1 study (-/1) | 88.0 % | NA | not evaluable | | non important | - |
| Guillain-Barré syndrome | 0.83 [0.56, 1.22] | | < 1 | | 0% | 3 studies (-/3) | 83.2 % | NA | not evaluable | | non important | - |
| Herpes simplex infection | 1.13 [0.94, 1.36] | | < 1 | | 0% | 1 study (-/1) | 10.0 % | NA | not evaluable | | non important | - |
| herpes zoster infection | 1.25 [0.94, 1.66] | | < 1 | | 73% | 2 studies (-/2) | 6.3 % | moderate | not evaluable | moderate | non important | - |
| immune thrombocytopenia | 1.12 [0.64, 1.95] | | < 1 | | 0% | 1 study (-/1) | 34.4 % | NA | not evaluable | | non important | - |
| intracranial hemorrhage | 0.83 [0.33, 2.08] | | < 1 | | 83% | 2 studies (-/2) | 65.4 % | moderate | not evaluable | moderate | non important | - |
| ischemic stroke | 0.98 [0.89, 1.07] | | < 1 | | 0% | 2 studies (-/2) | 70.1 % | critical | not evaluable | very low | non important | - |
| life-threatening SAE | 0.91 [0.51, 1.65] | | < 1 | | 0% | 1 study (1/-) | 61.8 % | NA | not evaluable | | non important | - |
| Myocardial infarction | 1.04 [0.93, 1.16] | | < 1 | | 0% | 3 studies (-/3) | 24.9 % | critical | not evaluable | very low | non important | - |
| myocarditis | 1.40 [0.96, 2.04] | | < 1 | | 36% | 3 studies (-/3) | 3.9 % | moderate | not evaluable | moderate | non important | - |
| neutropenia | 0.87 [0.46, 1.65] | | < 1 | | 0% | 1 study (-/1) | 66.5 % | NA | not evaluable | | non important | - |
| paresthesia | 1.18 [1.09, 1.28] | | < 1 | | 20% | 2 studies (-/2) | 0.0 % | moderate | not evaluable | moderate | non important | - |
| pericarditis | 1.21 [0.86, 1.70] | | < 1 | | 0% | 2 studies (-/2) | 13.9 % | critical | not evaluable | very low | non important | - |
| pulmonary embolism | 1.03 [0.86, 1.24] | | < 1 | | 29% | 3 studies (-/3) | 36.6 % | critical | not evaluable | very low | non important | - |
| severe adverse events | 1.74 [1.41, 2.14] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| thrombocytopenia | 0.94 [0.66, 1.33] | | < 1 | | 0% | 1 study (-/1) | 63.5 % | NA | not evaluable | | non important | - |
| Transverse myelitis | 1.45 [0.07, 31.68] | | < 1 | | 0% | 1 study (-/1) | 40.8 % | NA | not evaluable | | non important | - |
| uveitis | 1.27 [0.64, 2.52] | | < 1 | | 0% | 1 study (-/1) | 24.7 % | NA | not evaluable | | non important | - |
| venous thromboembolism | 1.16 [1.00, 1.34] | | < 1 | | 0% | 1 study (-/1) | 2.3 % | NA | not evaluable | | non important | - |
| VTE with thrombocytopenia | 0.86 [0.58, 1.27] | | < 1 | | 0% | 1 study (-/1) | 77.5 % | NA | not evaluable | | non important | - |
AE of interest endpoints 00 |
| cerebral venous sinus thrombosis (CVST) | 1.30 [0.45, 3.73] | | < 1 | | 0% | 3 studies (-/3) | 31.5 % | moderate | not evaluable | moderate | important | - |
| appendicitis | 1.14 [0.69, 1.86] | | < 1 | | 81% | 3 studies (1/2) | 30.8 % | critical | not evaluable | very low | non important | - |
| Bell's palsy | 1.05 [0.88, 1.26] | | < 1 | | 64% | 10 studies (1/9) | 28.9 % | low | low | high | non important | - |
| hypersensitivity, all terms | 2.17 [0.82, 5.71] | | < 1 | | 0% | 1 study (1/-) | 5.9 % | NA | not evaluable | | non important | - |
| immediate allergic reaction | 1.00 [0.02, 50.42] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| lymphadenopathy, any | 4.80 [1.13, 20.41] | | < 1 | | 91% | 2 studies (1/1) | 1.7 % | serious | not evaluable | low | non important | - |
| musculoskeletal and connective tissue disorders, any | 3.65 [3.26, 4.09] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| myelitis | 1.05 [0.77, 1.43] | | < 1 | | 14% | 2 studies (-/2) | 37.5 % | NA | not evaluable | | non important | - |
reactogenicity (vaccines) endpoints 00 |
| local adverse reaction, any, dose 1 | 24.90 [22.13, 28.03] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| local adverse reaction, any, dose 2 | 23.04 [20.30, 26.15] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| systemic adverse reaction, any, dose 1 | 1.63 [1.50, 1.78] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| systemic adverse reaction, any, dose 2 | 4.55 [4.13, 5.01] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
immunogenicity (vaccines) endpoints 00 |
| serologic response (seroconversion) | 0.09 [0.00, 5.02] | | > 1 | | 70% | 2 studies (-/2) | 12.4 % | NA | not evaluable | | non important | - |
